0000000000875707

AUTHOR

Ronald Van Leersum

showing 3 related works from this author

Consensus molecular subtypes of colorectal cancer are recapitulated in in vitro and in vivo models

2018

Colorectal cancer (CRC) is a highly heterogeneous disease both from a molecular and clinical perspective. Several distinct molecular entities, such as microsatellite instability (MSI), have been defined that make up biologically distinct subgroups with their own clinical course. Recent data indicated that CRC can be best segregated into four groups called consensus molecular subtypes (CMS1-4), each of which has a unique biology and gene expression pattern. In order to develop improved, subtype-specific therapies and to gain insight into the molecular wiring and origin of these subtypes, reliable models are needed. This study was designed to determine the heterogeneity and identify the prese…

0301 basic medicineStromal cellColorectal cancerCellMice NudeAntineoplastic AgentsApoptosisComputational biologyBiologyModels BiologicalArticle03 medical and health sciencesMiceStructure-Activity Relationship0302 clinical medicineIn vivomedicineBiomarkers TumorTumor Cells CulturedAnimalsHumansMolecular BiologyCell ProliferationRegulation of gene expressionDose-Response Relationship DrugGene Expression ProfilingMesenchymal stem cellMicrosatellite instabilityCell DifferentiationNeoplasms ExperimentalCell Biologymedicine.diseaseGene expression profilingGene Expression Regulation NeoplasticOxaliplatin030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisFluorouracilDrug Screening Assays AntitumorColorectal NeoplasmsCell death and differentiation
researchProduct

Capturing colorectal cancer inter-tumor heterogeneity in patient-derived xenograft (PDX) models

2018

Patient-derived xenograft (PDX) models have become an important asset in translational cancer research. However, to provide a robust preclinical platform, PDXs need to accommodate the tumor heterogeneity that is observed in patients. Colorectal cancer (CRC) can be stratified into four consensus molecular subtypes (CMS) with distinct biological and clinical features. Surprisingly, using a set of CRC patients, we revealed the partial representation of tumor heterogeneity in PDX models. The epithelial subtypes, the largest subgroups of CRC subtype, were very ineffective in establishing PDXs, indicating the need for further optimization to develop an effective personalized therapeutic approach …

OncologyCancer Researchmedicine.medical_specialtyPartial representationColorectal cancerbusiness.industryTumor cellsmedicine.diseaseTumor heterogeneityTumor Subtype03 medical and health sciencesTherapeutic approach0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicinemedicineIn patientbusinessInternational Journal of Cancer
researchProduct

Capturing colorectal cancer inter-tumor heterogeneity in patient-derived xenograft (PDX) models

2019

Patient‐derived xenograft (PDX) models have become an important asset in translational cancer research. However, to provide a robust preclinical platform, PDXs need to accommodate the tumor heterogeneity that is observed in patients. Colorectal cancer (CRC) can be stratified into four consensus molecular subtypes (CMS) with distinct biological and clinical features. Surprisingly, using a set of CRC patients, we revealed the partial representation of tumor heterogeneity in PDX models. The epithelial subtypes, the largest subgroups of CRC subtype, were very ineffective in establishing PDXs, indicating the need for further optimization to develop an effective personalized therapeutic approach …

Tumor Markers and SignaturesCMSShort Reportcolorectal cancerXenograft Model Antitumor AssaysDisease Models AnimalMicecell proliferationxenograft CMStumor subtypeAnimalsHeterograftsHumansxenograftColorectal NeoplasmsPDX
researchProduct